Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31569184 | 0.87 | PTPN1 (0.47) | PTPN1HDAC8NR1D1NAMPTACE | |
| SCHEMBL29443079 | 0.83 | PTPN1 (0.65) | PTPN1HDAC8NR1D1NAMPT | |
| SCHEMBL21490343 | 0.83 | PTPN1 (0.65) | PTPN1HDAC8NR1D1NAMPT | |
| SCHEMBL2737917 | 0.83 | PTPN1 (0.65) | PTPN1HDAC8NR1D1NAMPT | |
| SCHEMBL14067913 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE | |
| SCHEMBL66872 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE | |
| SCHEMBL2080858 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE | |
| SCHEMBL29401053 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE | |
| SCHEMBL66871 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE | |
| SCHEMBL29707284 | 0.80 | ACE (0.59) | PTPN1HDAC8ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012164085-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20020072604-A1 | Melanocortin receptor ligands | CARPINO PHILIP A (US) | 2002-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072604-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC3R | PTPN1 1296/4885HDAC8 3340/4885NR1D1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.